Browsing by Author "Guven, Deniz Can"
Now showing items 1-10 of 10
-
Antibody responses to COVID-19 vaccination in cancer: a systematic review
Guven, Deniz Can; Sahin, Taha Koray; Kilickap, Saadettin; Uckun, Fatih M. (Frontiers Media SA, 2021)Introduction: After the results of phase III vaccine studies became available, the leading oncology societies recommended two doses of COVID-19 vaccination to all patients with cancer with no specific recommendation for ... -
The association between albumin-globulin ratio (AGR) and survival in patients treated with immune checkpoint inhibitors
Guven, Deniz Can; Aktepe, Oktay Halit; Aksun, Melek Seren; Sahin , Taha Koray; Kavgaci, Gozde; Ucgul, Enes; Cakir, Ibrahim Yahya; Yildirim, Hasan Cagri; Guner, Gurkan; Akin, Serkan; Kertmen, Neyran; Dizdar, Omer; Aksoy, Sercan; Erman, Mustafa; Suayib, Yalcin; Kilickap, Saadettin (IOS Press, 2022)BACKGROUND: The albumin-globulin ratio (AGR) could be a prognostic biomarker in patients with cancer, although the data is limited in patients treated with immune-checkpoint inhibitors (ICIs). OBJECTIVES: We aimed to ... -
The association between antibiotic use and survival in renal cell carcinoma patients treated with immunotherapy: a multi-center study
Guven, Deniz Can; Acar, Ramazan; Yekedüz, Emre; Bilgetekin, İrem; Baytemur, Naziyet Kose; Erol, Cihan; Ceylan, Furkan Sacit; Kılıçkap, Saadettin (Mosby Inc., 2021)Background: Immunotherapy improves overall survival (OS) in the second and later lines of renal cell carcinoma (RCC) treatment. Recent studies have suggested that antibiotic (ATB) use either shortly before or after the ... -
The association between early changes in neutrophil-lymphocyte ratio and survival in patients treated with immunotherapy
Guven, Deniz Can; Sahin, Taha Koray; Erul, Enes; Cakir, Ibrahim Yahya; Ucgul, Enes; Yildirim, Hasan Cagri; Aktepe, Oktay Halit; Erman, Mustafa; Kilickap, Saadettin; Aksoy, Sercan; Yalcin, Suayib (MDPI, 2022)Dynamic changes in the blood-based biomarkers could be used as a prognostic biomarker in patients treated with immune checkpoint inhibitors (ICIs), although the data are limited. We evaluated the association between the ... -
The Association between the Pan-Immune-Inflammation Value and Cancer Prognosis: A systematic review and meta-analysis
Guven, Deniz Can; Sahin, Taha Koray; Erul, Enes; Kilickap, Saadettin; Gambichler, Thilo; Aksoy, Sercan (PMC, 2022)Background: Prognostic scores derived from the blood count have garnered significant interest as an indirect measure of the inflammatory pressure in cancer. The recently developed pan-immune-inflammation value (PIV), an ... -
The benefit of treatment beyond progression with immune checkpoint inhibitors: A multi-center retrospective cohort study
Guven, Deniz Can; Yekeduz, Emre; Erul, Enes; Coskun Yazgan, Sati; Sahin, Taha Koray; Karatas, Gokturk; Aksoy, Sercan; Erman, Mustafa; Yalcin, Suayib; Urun, Yuksel; Kilickap, Saadettin (Springer, 2022)Objective: Treatment beyond progression (TBP) with immune checkpoint inhibitors (ICIs) is an evolving field due to the limitations of conventional imaging in response evaluation. However, real-life data on the benefit of ... -
Blood based biomarkers as predictive factors for hyperprogressive disease
Yildirim, Hasan Cagri; Guven, Deniz Can; Aktepe, Oktay Halit; Taban, Hakan; Yilmaz, Feride; Yasar, Serkan; Aksoy, Sercan; Erman, Mustafa; Kilickap, Saadettin; Yalcin, Suayib (MDPI, 2022)Purpose: With the widespread use of immunotherapy agents, we encounter treatment responses such as hyperprogression disease (HPD) that we have not seen with previous standard chemotherapy and targeted therapies. It is known ... -
Crizotinib efficacy after progression with entrectinib in ROS1-Positive lung cancer: a case report
Taban, Hakan; Guven, Deniz Can; Kilickap, Saadettin (CUREUS INC, 2022)Crizotinib and entrectinib are approved tyrosine kinase inhibitors by the FDA to treat advanced-stage ROS1-positive non-small cell lung cancer (NSCLC). Although, entrectinib could be used after crizotinib, it is unknown ... -
Differences between hyperprogressive disease and progressive disease in patients receiving immunotherapy
Yildirim, Hasan Cagri; Guven, Deniz Can; Aktepe, Oktay Halit; Taban, Hakan; Yilmaz, Feride; Yasar, Serkan; Aktas, Burak Yasin; Guner, Gurkan; Dizdar, Omer; Aksoy, Sercan; Erman, Mustafa; Yalcin, Suayib; Kilickap, Saadettin (Kare Publishing, 2022)Objectives: Although immune checkpoint inhibitors (ICIs) became a vital part of cancer care, many patients do not respond to treatment. In this group, a few of the patients with a hyperprogressive disease (HPD) have shorter ... -
Newly diagnosed cancer and the COVID-19 pandemic: tumour stage migration and higher early mortality
Guven, Deniz Can; Sahin, Taha Koray; Yildirim, Hasan Cagri; Cesmeci, Engin; Gulbahce Incesu, Fatima Gul; Kilickap, Saadettin (BMJ, 2021)Background: We compared the new outpatient clinic referrals during the first 10 months of the COVID-19 pandemic with the year before. Methods: We compared baseline characteristics of the 2208 new referrals in 2020 (n=922) ...
